We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?
Read MoreHide Full Article
Intellia Therapeutics, Inc. (NTLA - Free Report) shares ended the last trading session 29.8% higher at $16.11. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 21.6% gain over the past four weeks.
The stock rallied after the company announced that it has completed enrollment in the pivotal phase III HAELO study evaluating its investigational candidate, lonvoguran ziclumeran (lonvo-z) for treating patients with hereditary angioedema (HAE). Top-line data from the HAELO study is expected in the first half of 2026.
Intellia remains on track to submit a potential biologics license application for lonvo-z for treating HAE in the second half of 2026. Upon potential approval, the company plans to launch lonvo-z in the United States in 2027.
This company is expected to post quarterly loss of $1.01 per share in its upcoming report, which represents a year-over-year change of +24.6%. Revenues are expected to be $14.38 million, up 57.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Intellia Therapeutics, the consensus EPS estimate for the quarter has been revised 0.5% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on NTLA going forward to see if this recent jump can turn into more strength down the road.
Intellia Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. CG Oncology, Inc. (CGON - Free Report) , another stock in the same industry, closed the last trading session 2.9% higher at $38.82. CGON has returned 47.8% in the past month.
CG Oncology, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.57. Compared to the company's year-ago EPS, this represents a change of -90%. CG Oncology, Inc. currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?
Intellia Therapeutics, Inc. (NTLA - Free Report) shares ended the last trading session 29.8% higher at $16.11. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 21.6% gain over the past four weeks.
The stock rallied after the company announced that it has completed enrollment in the pivotal phase III HAELO study evaluating its investigational candidate, lonvoguran ziclumeran (lonvo-z) for treating patients with hereditary angioedema (HAE). Top-line data from the HAELO study is expected in the first half of 2026.
Intellia remains on track to submit a potential biologics license application for lonvo-z for treating HAE in the second half of 2026. Upon potential approval, the company plans to launch lonvo-z in the United States in 2027.
This company is expected to post quarterly loss of $1.01 per share in its upcoming report, which represents a year-over-year change of +24.6%. Revenues are expected to be $14.38 million, up 57.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Intellia Therapeutics, the consensus EPS estimate for the quarter has been revised 0.5% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on NTLA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Intellia Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. CG Oncology, Inc. (CGON - Free Report) , another stock in the same industry, closed the last trading session 2.9% higher at $38.82. CGON has returned 47.8% in the past month.
CG Oncology, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.57. Compared to the company's year-ago EPS, this represents a change of -90%. CG Oncology, Inc. currently boasts a Zacks Rank of #3 (Hold).